Cancer treatment-related cardiotoxicity: Current state of knowledge and future research priorities

Journal of the National Cancer Institute

Volumn 106, Issue 9, 2014, Pages

  Shelburne, Nonniekaye ^a   Adhikari, Bishow ^b   Brell, Joanna ^a,c   Davis, Myrtle ^a   Desvigne Nickens, Patrice ^b   Freedman, Andrew ^a   Minasian, Lori ^a   Force, Thomas ^d   Remick, Scot C ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PATIENT; CANCER RESEARCH; CANCER SCREENING; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; COMMON DATA ELEMENTS; COMORBIDITY; CONSENSUS; EARLY INTERVENTION; HEALTH PRACTITIONER; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HUMAN; HYPERTENSION; MEDICAL LITERATURE; NONHUMAN; PATIENT ADVOCACY; PATIENT CARE; PATIENT SAFETY; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESEARCH PRIORITY; REVIEW; RODENT MODEL; THREE DIMENSIONAL ECHOCARDIOGRAPHY; TISSUE DOPPLER IMAGING; TREATMENT OUTCOME; TREATMENT PLANNING; WORKSHOP; CHEMICALLY INDUCED DISORDER; CONFERENCE PAPER; DRUG EFFECT; EDUCATION; HEALTH CARE PERSONNEL; HEART; HEART DISEASE; MUSCLE CELL; NATIONAL HEALTH ORGANIZATION; NEOPLASM; UNITED STATES;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; HEALTH PERSONNEL; HEART; HEART DISEASES; HUMANS; MUSCLE CELLS; NATIONAL CANCER INSTITUTE (U.S.); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); NEOPLASMS; UNITED STATES;

EID: 84927671972     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju232     Document Type: Review

References (47)

1. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241.
2. Mertens AC, Yasui Y, Neglia J P, et al. Late mortality experience in fiveyear survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 2001;19(13):3163-3172.
3. Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer-a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2010;19(1):170-181.
4. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231-2247.
5. Schultz PN, Beck ML, Stava C, et al. Health profiles in 5836 long-term cancer survivors. Int J Cancer. 2003;104(4):488-495.
6. Curigliano G, Mayer EL, Burstein HJ, et al. Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010;53(2):94-104.
7. Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013;128(17):1927-1995.
8. Travis LB, Ng AK, Allan JM, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst. 2012;104(5):357-370.
9. National Cancer Institute. Cancer Treatment-Related Cardiotoxicity: Understanding the Current State of Knowledge and Developing Future Research Priorities. http://epi.grants.cancer.gov/workshops/cardiotoxicity/Accessed August 11, 2014.
10. National Institutes of Health Videocasting and Podcasting. Cancer Treatment Related Cardiotoxicity Day 1. http://videocast.nih.gov/summary.asp?live=11985&bhcp=1 Accessed August 11, 2014.
11. National Institutes of Health Videocasting and Podcasting. Cancer Treatment Related Cardiotoxicity Day 2. http://videocast.nih.gov/summary.asp?live=11987&bhcp=1 Accessed August 11, 2014.
12. American Heart Association. Statements & Guidelines. http://my.americanheart.org/professional/StatementsGuidelines/Statements-Guidelines-UCM-316885-SubHomePage.jsp Accessed August 11, 2014.
13. National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 4.0 http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Accessed August 11, 2014.
14. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol. 1998;25(4 Suppl 10):10-14.
15. Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol. 2005;68(2):261-271.
16. Force T, Wang Y. Mechanism-based engineering against anthracycline cardiotoxicity. Circulation. 2013;128(2):98-100.
17. Jay SM, Murthy AC, Hawkins JF, et al. An engineered bivalent neuregulin protects against doxorubicin-induced cardiotoxicity with reduced proneoplastic potential. Circulation. 2013;128(2):152-161.
18. Ky B, Vejpongsa P, Yeh ET, et al. Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ Res. 2013;113(6):754-764.
19. Eschenhagen T, Force T, Ewer MS, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011;13(1):1-10.
20. Clements M, Thomas N. High-Throughput Multi-Parameter Profiling of Electrophysiological Drug Effects in Human Embryonic Stem Cell Derived Cardiomyocytes Using Multi-Electrode Arrays. Toxicol Sci. 2014; doi:10.1093/toxsci/kfu084.
21. Liang P, Lan F, Lee AS, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013;127(16):1677-1691.
22. Kitambi SS, Nilsson ES, Sekyrova P, et al. Small molecule screening platform for assessment of cardiovascular toxicity on adult zebrafish heart. BMC Physiol. 2012;12:3.
23. Takimoto CH, Mita AC. Design, conduct, and interpretation of organ impairment studies in oncology patients. J Clin Oncol. 2006;24(21):3509-3510; author reply 3510-1.
24. Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst. 2010;102(9):596-604.
25. Steingart RM, Bakris GL, Chen HX, et al. Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. Am Heart J. 2012;163(2):156-163.
26. Sawaya H, Sebag IA, Plana JC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5(5):596-603.
27. Sawaya H, Sebag IA, Plana JC, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107(9):1375-1380.
28. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749-2754.
29. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined - a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36(3):959-969.
30. Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63(8):809-816.
31. Motiwala SR, Szymonifka J, Belcher A, et al. Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. J Cardiovasc Transl Res. 2014;7(2):250-261.
32. Vassiliadis E, Rasmussen LM, Byrjalsen I, et al. Clinical evaluation of a matrix metalloproteinase-12 cleaved fragment of titin as a cardiovascular serological biomarker. J Transl Med. 2012;10:140.
33. Jiji RS, Kramer CM, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol. 2012;19(2):377-388.
34. Aissiou M, Perie D, Cheriet F, et al. Imaging of early modification in cardiomyopathy: the doxorubicin-induced model. Int J Cardiovasc Imaging. 2013;29(7):1459-1476.
35. Gillespie HS, McGann CJ, Wilson BD. Noninvasive diagnosis of chemotherapy related cardiotoxicity. Curr Cardiol Rev. 2011;7(4):234-244.
36. De Geus-Oei LF, Mavinkurve-Groothuis AM, Bellersen L, et al. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. J Nucl Med Technol. 2013;41(3):170-181.
37. Karamitsos TD, Neubauer S. The prognostic value of late gadolinium enhancement CMR in nonischemic cardiomyopathies. Curr Cardiol Rep. 2013;15(1):326.
38. Lindenfeld J, Kelly PA. Developing a cardiology-oncology clinical practice guideline. Prog Cardiovasc Dis. 2010;53(2):173-179.
39. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-1847.
40. National Comprehensive Cancer Network. NCCN Practice Guidelines. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#detection Accessed August 11, 2014.
41. Diller L, Chow EJ, Gurney JG, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol. 2009;27(14):2339-2355.
42. Kremer LC, Van Der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002;13(6):819-829.
43. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012;4:CD006243.
44. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010;10:337.
45. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869-2879.
46. Schmitz KH, Prosnitz RG, Schwartz AL, et al. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors. Cancer. 2012;118(8 Suppl):2270-2276.
47. Institute of Medicine. Patient-Centered Cancer Treatment Planning: Improving the Quality of Oncology Care: Workshop Summary.. Washington, DC: The National Academies Press, 2011. http://www.nap.edu/openbook. php?record-id=13155. Accessed August 11, 2014.